MX2022001748A - Métodos para prevenir una enfermedad relacionada con la inmunoglobulina e. - Google Patents

Métodos para prevenir una enfermedad relacionada con la inmunoglobulina e.

Info

Publication number
MX2022001748A
MX2022001748A MX2022001748A MX2022001748A MX2022001748A MX 2022001748 A MX2022001748 A MX 2022001748A MX 2022001748 A MX2022001748 A MX 2022001748A MX 2022001748 A MX2022001748 A MX 2022001748A MX 2022001748 A MX2022001748 A MX 2022001748A
Authority
MX
Mexico
Prior art keywords
preventing
related disease
immunoglobulin
methods
subject
Prior art date
Application number
MX2022001748A
Other languages
English (en)
Inventor
Ron Kohn
Michael Brandwein
Ariel Katz
Original Assignee
My Or Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by My Or Diagnostics Ltd filed Critical My Or Diagnostics Ltd
Publication of MX2022001748A publication Critical patent/MX2022001748A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a un método para determinar la idoneidad de un sujeto para una terapia de restauración de la barrera cutánea. Además, se proporciona un método para seleccionar y prevenir una enfermedad relacionada con la IgE en un sujeto que lo necesite.
MX2022001748A 2019-08-11 2020-08-11 Métodos para prevenir una enfermedad relacionada con la inmunoglobulina e. MX2022001748A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962885263P 2019-08-11 2019-08-11
US202062989754P 2020-03-15 2020-03-15
PCT/IL2020/050875 WO2021028908A1 (en) 2019-08-11 2020-08-11 Methods for preventing an immunoglobulin e-related disease

Publications (1)

Publication Number Publication Date
MX2022001748A true MX2022001748A (es) 2022-04-07

Family

ID=74571015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001748A MX2022001748A (es) 2019-08-11 2020-08-11 Métodos para prevenir una enfermedad relacionada con la inmunoglobulina e.

Country Status (5)

Country Link
US (1) US20220313768A1 (es)
EP (1) EP4010000A4 (es)
CN (1) CN114728035A (es)
MX (1) MX2022001748A (es)
WO (1) WO2021028908A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1169838C (zh) * 2001-12-14 2004-10-06 中国科学院微生物研究所 乙酰甘露聚糖及其制备方法和应用
KR100723251B1 (ko) * 2005-03-18 2007-05-29 전숙영 알레르기 질환의 치료를 위한 약학적 조성물, 그의 용도 및알레르기 질환의 치료방법
EP2238981B1 (en) * 2007-09-21 2014-07-23 Pharmabrand S.A. Composition comprising mucilaginous polysaccharides derived from aloe barbadensis combined with liposomes, method for obtaining same and use thereof as a sun protector, an anti-acne agent, an epidermal regenerator and a moisturiser
GB2459121A (en) * 2008-04-10 2009-10-14 Prime Interaction Holdings Ltd A product for topical administration

Also Published As

Publication number Publication date
WO2021028908A1 (en) 2021-02-18
CN114728035A (zh) 2022-07-08
EP4010000A1 (en) 2022-06-15
EP4010000A4 (en) 2023-08-16
US20220313768A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
CO2020014773A2 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
ZA201804513B (en) Method of treating c3 glomerulopathy
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
MD3455259T2 (ro) Combinație de anticorpi anti-PD-1 și radiație pentru tratarea cancerului
SG11202100320QA (en) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
CO2020012588A2 (es) Composiciones de inhibidores de shp2, métodos para tratar el cáncer y metodos para identificar a un sujeto con mutaciones de shp2
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
SA518391722B1 (ar) أجسام مضادة تستهدف شبيه مستقبل Fc5 وطرق استخدامها
EP4257134A3 (en) Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
GT201200318A (es) Anticuerpos hacia gdf8 humano
ECSP15005280A (es) Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos
LT4032052T (lt) Operacijų vykdymas, naudojant privačias ir viešąsias blokų grandines
ECSP20063690A (es) Anticuerpos
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
ZA202103429B (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MX2019005443A (es) Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer.
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
IL290111A (en) Methods for administration of anti-siglec-8 antibodies and corticosteroids
EP4342544A3 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
BR112023023787A2 (pt) Terapêuticas bispecíficas à base de il2 e anti-pd-1 e métodos de utilização das mesmas
MX2022001748A (es) Métodos para prevenir una enfermedad relacionada con la inmunoglobulina e.
MX2021003298A (es) Métodos para revertir la actividad ticagrelor.